Bold Moves

Deliver first-in-class science

Win the digital race in pharma

Tanezumab is under regulatory review for chronic pain due to moderate-to-severe osteoarthritis (OA), a debilitating condition that impacts millions around the world

Pfizer is driven by a desire to improve the lives of millions of patients suffering from OA, a leading cause of chronic pain and disability worldwide.1,2 OA can have life-altering physical, social, psychological and economic impacts for patients, their loved ones and society.3,4,5 Currently available treatment options for moderate-to-severe OA do not meet all patients’ needs, and many cycle through multiple therapies to find relief from their pain. Pfizer is committed to raising awareness and understanding of the burden of chronic OA pain and the significant unmet needs for patients, and to driving innovation in the treatment of this debilitating condition.

With her daughter and caregiver, Lizzie, Ann shares the impact chronic OA pain has had on their relationship.


​​​​Together with Eli Lilly and Company, Pfizer is leveraging our deep clinical expertise to progress tanezumab, a potential first-in-class treatment for chronic OA pain. Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor inhibitors. Regulatory applications for tanezumab 2.5 mg administered subcutaneously have been accepted for review in the U.S., EU and Japan for the treatment of adult patients with chronic pain due to moderate-to-severe OA for whom the use of other analgesics is ineffective or inappropriate, with regulatory decisions expected in 2021. The applications were the largest Pfizer has ever dispatched, and their breadth reflects our commitment and the extensive clinical evidence gathered for tanezumab.

 31 million

In the U.S. alone, approximately 31 million people have OA, and about 40% of patients experience moderate or severe OA.6,7​​​​​​​


1Rice D, McNair P, Huysmans E, Letzen J, Finan P. Best evidence rehabilitation for chronic pain part 5: Osteoarthritis. J Clin Med. 2019;8(11):1769.

2GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789-1858.

3Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393:1745-1759.

4White AG, Birnbaum HG, Janagap C, Buteau S, Schein J. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States. J Occup Environ Med. 2008;50:998-1005.

5Siviero P, Veronese N, Smith T, et al. Association between osteoarthritis and social isolation: data from the EPOSA study. J Am Geriatr Soc. 2020;68(1):87-95.
6Cisternas MG, Murphy L, Sacks JJ, et al. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res. 2016;68(5):574-80.

7Zhao X, Shah D, Gandhi K, et al. Clinical, humanistic, and economic burden of osteoarthritis among noninstitutionalized adults in the United States. Osteoarthritis Cartilage. 2019;27(11):1618-1626.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories